{"id":2408,"date":"2026-08-03T09:00:00","date_gmt":"2026-08-03T13:00:00","guid":{"rendered":"https:\/\/www.insilens.com\/?p=2408"},"modified":"2026-08-04T20:20:30","modified_gmt":"2026-08-05T00:20:30","slug":"voyxact-preserves-kidney-function-at-two-years-in-iga-nephropathy","status":"publish","type":"post","link":"https:\/\/www.insilens.com\/?p=2408","title":{"rendered":"VOYXACT Preserves Kidney Function at Two Years in IgA Nephropathy"},"content":{"rendered":"

Company:<\/strong> Otsuka Pharmaceutical · Event Type:<\/strong> Phase III Data (24-Month, Detailed) · Product:<\/strong> VOYXACT (sibeprenlimab-szsi) · Indication:<\/strong> Primary IgA Nephropathy · Presentation:<\/strong> GlomCon, August 3, 2026<\/p>\n

\"VOYXACT<\/p>\n

Summary<\/h4>\n

Otsuka presented complete 24-month Phase III VISIONARY results showing a prespecified annualized eGFR slope of +0.3 mL\/min\/1.73 m²\/year with VOYXACT versus −4.2 with placebo, a treatment difference of +4.5 with p<0.0001. The detailed conference data materially strengthen the evidence supporting conversion of VOYXACT’s accelerated U.S. approval in IgA nephropathy to traditional approval.<\/p>\n

The randomized 530-participant study links selective APRIL inhibition to preservation of kidney function beyond the proteinuria surrogate that supported initial approval. The result is clinically important and safety was comparable to placebo through two years, but the analysis remains company-reported pending full peer review, and long-term outcomes beyond two years remain unknown.<\/p>\n

What Happened<\/h4>\n

The late-breaking GlomCon presentation provided numerical detail that was not available in Otsuka’s July 1 topline disclosure. The annualized eGFR-slope difference was +4.5 mL\/min\/1.73 m²\/year with a 95% confidence interval of 3.6 to 5.4. Least-squares mean change from baseline at month 24 was +1.3 with VOYXACT versus −7.9 with placebo, a difference of +9.2 with p<0.0001.<\/p>\n

Overall adverse events occurred in 90.7% of VOYXACT recipients and 90.0% of placebo recipients. Infections and infestations occurred in 51.4% and 51.0%, injection-site reactions in 35.1% and 32.2%, and serious infections in 1.9% and 4.0%, respectively. Otsuka reported no new safety signal and lower rates of serious or severe adverse events and discontinuations with VOYXACT.<\/p>\n

VOYXACT received accelerated U.S. approval in November 2025 to reduce proteinuria in adults with primary IgA nephropathy at risk for progression. The approved label explicitly stated that long-term slowing of kidney-function decline had not been established. Otsuka is using the 24-month dataset in a rolling supplemental application for traditional approval.<\/p>\n

Clinical Significance and Mechanism<\/h4>\n

eGFR slope is closer to irreversible kidney outcome than proteinuria and is the key confirmatory measure for this accelerated approval. A treatment effect of 4.5 mL\/min\/1.73 m²\/year is large relative to the placebo decline and, if sustained, could delay kidney failure. The confidence intervals and prespecified mixed-effects model support statistical robustness, while the complementary change-from-baseline analysis points in the same direction.<\/p>\n

Sibeprenlimab is a humanized monoclonal antibody that blocks APRIL, reducing production of galactose-deficient IgA1 that participates in pathogenic immune-complex formation. Selective APRIL inhibition aims to reduce disease-driving antibody biology without broad B-cell depletion. Comparable infection rates are reassuring, but immune suppression and vaccine-response risks remain part of the label.<\/p>\n

Evidence Limitations<\/h4>\n

The detailed 24-month results were presented at a conference and in a company release; full peer-reviewed methods, missing-data handling and subgroup interaction testing are not yet available. VISIONARY enrolled adults with eGFR at least 30 and proteinuria despite optimized supportive therapy, so generalization to lower-risk disease, advanced kidney failure or pediatric patients is not established.<\/p>\n

Reading the Signal<\/h4>\n

One plausible reading is that VOYXACT has verified disease-modifying benefit and should satisfy the principal clinical requirement for traditional approval. Supporting evidence includes randomization, a prespecified key secondary endpoint, large separation from placebo and internally consistent safety. Contradicting evidence is the absence of full peer review and uncertainty about durability beyond two years.<\/p>\n

A second plausible reading is that the favorable slope may overstate long-term benefit if early hemodynamic effects, dropout or model assumptions influence the estimate. Supporting evidence is that slope analyses depend on repeated-measures assumptions. Against this interpretation, the month-24 change-from-baseline analysis also favored VOYXACT substantially and the mechanism directly targets pathogenic IgA production.<\/p>\n

The interpretation would be upgraded by traditional FDA approval, peer-reviewed individual-patient analyses, consistent subgroup effects and durable protection in the extension study. It would be downgraded by sensitivity analyses that materially reduce the effect, delayed infection signals or waning eGFR benefit. Failure of confirmatory regulatory review or loss of separation in longer follow-up would falsify the current durability thesis.<\/p>\n

Signal Extraction<\/h4>\n
    \n
  • Enrollment:<\/strong> 530 adults with biopsy-confirmed primary IgA nephropathy.<\/li>\n
  • Key endpoint:<\/strong> Annualized eGFR slope +0.3 versus −4.2 mL\/min\/1.73 m²\/year; difference +4.5, p<0.0001.<\/li>\n
  • Month-24 change:<\/strong> +1.3 versus −7.9; difference +9.2, p<0.0001.<\/li>\n
  • Safety:<\/strong> Overall adverse events and infections were similar to placebo through 24 months.<\/li>\n
  • Regulatory status:<\/strong> Accelerated approval remains in place; rolling traditional-approval submission is ongoing.<\/li>\n<\/ul>\n

    InSilens Take<\/h4>\n

    This is a 5\/5 positive\/mixed signal. The detailed two-year result directly addresses the clinical-benefit uncertainty in the accelerated-approval label and is statistically and clinically persuasive. Direction remains mixed because full regulatory conversion and peer-reviewed scrutiny are outstanding, and the report should not be interpreted as proof of lifetime kidney protection.<\/p>\n

    Company and Product Background<\/h4>\n

    Otsuka Pharmaceutical develops and commercializes medicines across nephrology, neuroscience and other therapeutic areas. VOYXACT, or sibeprenlimab-szsi, is a self-administered subcutaneous APRIL-blocking antibody dosed every four weeks.<\/p>\n

    IgA nephropathy is an immune-mediated glomerular disease driven in part by galactose-deficient IgA1 and pathogenic immune complexes. Persistent proteinuria and declining eGFR predict progression to kidney failure. Standard management includes renin-angiotensin blockade, SGLT2 inhibition and disease-targeted therapies for patients at continued risk.<\/p>\n

    Signal Assessment<\/h4>\n

    Signal Importance: 5\/5. Signal Direction: positive\/mixed. Confidence in Facts: high — the trial is randomized and registered, and detailed numerical results were disclosed. Confidence in Interpretation: medium-high — peer review and regulatory adjudication remain pending.<\/p>\n

    Missing facts include the complete analysis plan, missing-data sensitivity tests, all subgroup results, neutralizing-antibody detail and longer-term extension outcomes.<\/p>\n","protected":false},"excerpt":{"rendered":"

    Otsuka presented complete 24-month Phase III VISIONARY results showing a prespecified annualized eGFR slope of +0.3 mL\/min\/1.73 m\u00b2\/year with VOYXACT versus \u22124.2 with placebo, a treatment difference of +4.5 with p<0.0001. The detailed conference...\n<\/p>\n","protected":false},"author":1,"featured_media":2419,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[11,3],"tags":[47,277,276],"class_list":["post-2408","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-clinical","category-therapeutic-indication","tag-iga-nephropathy","tag-kidney-disease","tag-otsuka-pharmaceutical"],"blocksy_meta":[],"_links":{"self":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/2408","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=2408"}],"version-history":[{"count":1,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/2408\/revisions"}],"predecessor-version":[{"id":2429,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/2408\/revisions\/2429"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/media\/2419"}],"wp:attachment":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=2408"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=2408"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=2408"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}